Jamie Rees
Research Subjects
Jamie Rees has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Raj Sharma
GlaxoSmithKline R&D, Brentford, UK
3 shared publications- Alison Moore
Global Medical Affairs, General Medicines, GSK, London WC1A 1DG, UK
2 shared publications Andrea Ludwig-Sengpiel
KLB Gesundheitsforschung Lübeck, Lübeck, Germany
2 shared publicationsAndrew Preece
GlaxoSmithKline R&D, Brentford, UK
2 shared publicationsGiselle Mosnaim
NorthShore University HealthSystem, Evanston, IL, USA
2 shared publicationsNeil Barnes
GlaxoSmithKline R&D, Brentford, UK
2 shared publications
Latest Publications
- Open Access
- 9 September 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (9) , e13873
Randomized, placebo‐controlled study on the effects of intravenous GSK3858279 (anti‐CCL17) on a battery of evoked pain tests in healthy participants
C–C Motif Chemokine Ligand 17 (CCL17) is a chemokine that binds and signals through the G‐protein coupled CC‐chemokine receptor 4 and has been implicated in the development of inflammatory and arthritic pain. GSK3858279 is a high‐affinity, first‐in‐class, monoclonal antibody, binding specifically to CCL17 and inhibiting downstream signaling. In this phase I, randomized, single‐center, double‐blind, placebo‐controlled, three‐period, incomplete‐block crossover study (NCT04114656), the analgesic effects and safety of intravenous GSK3858279 were assessed in a battery of evoked acute pain assessments on healthy, adult (aged ≥18 years), male participants. Participants were randomized 1:1 to receive either one placebo (0.9% w/v NaCl) dose followed by two GSK3858279 doses (PAA treatment sequence), or one GSK3858279 dose followed by two placebo doses (APP treatment sequence). The co‐primary end points were ultraviolet B heat pain detection threshold (°C), cold pressor time to pain tolerance threshold (PTT, sec), and electrical PTT (mA, single stimulus). Twenty‐one participants were enrolled (PAA = 11; APP = 10). Mean age (standard deviation) was 29.3 (7.9) years for PAA, 31.1 (7.7) years for APP. No significant differences were observed in the analgesic effect between GSK3858279 and placebo for any end point. Exposure to GSK3858279 was similar between Period 1 (APP sequence), and Periods 2 and 3 (PAA sequence), with some GSK3858279 carry‐over. Changes in serum CCL17 levels were consistent with the expected GSK3858279 activity. All drug‐related adverse events were mild in intensity and caused no discontinuations. The absence of an efficacy signal in this acute pain model does not preclude efficacy in chronic pain states.
- 9 September 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (9) , e13873
Open AccessRandomized, placebo‐controlled study on the effects of intravenous GSK3858279 (anti‐CCL17) on a battery of evoked pain tests in healthy participants
C–C Motif Chemokine Ligand 17 (CCL17) is a chemokine that binds and signals through the G‐protein coupled CC‐chemokine receptor 4 and has been implicated in the development of inflammatory and arthritic pain. GSK3858279 is a high‐affinity, first‐in‐class, monoclonal antibody, binding specifically to CCL17 and inhibiting downstream signaling. In this phase I, randomized, single‐center, double‐blind, placebo‐controlled, three‐period, incomplete‐block crossover study (NCT04114656), the analgesic effects and safety of intravenous GSK3858279 were assessed in a battery of evoked acute pain assessments on healthy, adult (aged ≥18 years), male participants. Participants were randomized 1:1 to receive either one placebo (0.9% w/v NaCl) dose followed by two GSK3858279 doses (PAA treatment sequence), or one GSK3858279 dose followed by two placebo doses (APP treatment sequence). The co‐primary end points were ultraviolet B heat pain detection threshold (°C), cold pressor time to pain tolerance threshold (PTT, sec), and electrical PTT (mA, single stimulus). Twenty‐one participants were enrolled (PAA = 11; APP = 10). Mean age (standard deviation) was 29.3 (7.9) years for PAA, 31.1 (7.7) years for APP. No significant differences were observed in the analgesic effect between GSK3858279 and placebo for any end point. Exposure to GSK3858279 was similar between Period 1 (APP sequence), and Periods 2 and 3 (PAA sequence), with some GSK3858279 carry‐over. Changes in serum CCL17 levels were consistent with the expected GSK3858279 activity. All drug‐related adverse events were mild in intensity and caused no discontinuations. The absence of an efficacy signal in this acute pain model does not preclude efficacy in chronic pain states.
- Open Access
- 17 December 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 57 (6) , 2003103
A randomised controlled trial of the effect of a connected inhaler system on medication adherence in uncontrolled asthmatic patients
Suboptimal adherence to maintenance therapy contributes to poor asthma control and exacerbations. This study evaluated the effect of different elements of a connected inhaler system (CIS), comprising clip-on inhaler sensors, a patient-facing app and a healthcare professional (HCP) dashboard, on adherence to asthma maintenance therapy.This was an open-label, parallel-group, 6-month, randomised controlled trial in adults with uncontrolled asthma (asthma control test (ACT) score less than 20) on fixed-dose inhaled corticosteroids/long-acting β-agonist maintenance therapy (n=437). All subjects received fluticasone furoate/vilanterol ELLIPTA dry-powder inhalers for maintenance and salbutamol/albuterol metered-dose inhalers for rescue, with a sensor attached to each inhaler. Participants were randomised to one of five CIS study arms (allocation ratio 1:1:1:1:1) reflecting the recipient of the data feedback from the sensors, as follows: 1) maintenance use to participants and HCPs (n=87); 2) maintenance use to participants (n=88); 3) maintenance and rescue use to participants and HCPs (n=88); 4) maintenance and rescue use to participants (n=88); and 5) no feedback (control) (n=86).For the primary endpoint, observed mean±sdadherence to maintenance therapy over months 4–6 was 82.2±16.58% (n=83) in the “maintenance to participants and HCPs” arm and 70.8±27.30% (n=85) in the control arm. The adjusted least squares mean±sewas 80.9±3.19% and 69.0±3.19%, respectively (study arm difference: 12.0%, 95% CI 5.2–18.8%; pversusthe control arm. The mean percentage of rescue medication free days (months 4–6) was significantly greater in participants receiving data on their rescue use compared with controls. ACT scores improved in all study arms with no significant differences between groups.A CIS can improve adherence to maintenance medication and reduce rescue medication use in patients with uncontrolled asthma.
- 17 December 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 57 (6) , 2003103
Open AccessA randomised controlled trial of the effect of a connected inhaler system on medication adherence in uncontrolled asthmatic patients
Suboptimal adherence to maintenance therapy contributes to poor asthma control and exacerbations. This study evaluated the effect of different elements of a connected inhaler system (CIS), comprising clip-on inhaler sensors, a patient-facing app and a healthcare professional (HCP) dashboard, on adherence to asthma maintenance therapy.This was an open-label, parallel-group, 6-month, randomised controlled trial in adults with uncontrolled asthma (asthma control test (ACT) score less than 20) on fixed-dose inhaled corticosteroids/long-acting β-agonist maintenance therapy (n=437). All subjects received fluticasone furoate/vilanterol ELLIPTA dry-powder inhalers for maintenance and salbutamol/albuterol metered-dose inhalers for rescue, with a sensor attached to each inhaler. Participants were randomised to one of five CIS study arms (allocation ratio 1:1:1:1:1) reflecting the recipient of the data feedback from the sensors, as follows: 1) maintenance use to participants and HCPs (n=87); 2) maintenance use to participants (n=88); 3) maintenance and rescue use to participants and HCPs (n=88); 4) maintenance and rescue use to participants (n=88); and 5) no feedback (control) (n=86).For the primary endpoint, observed mean±sdadherence to maintenance therapy over months 4–6 was 82.2±16.58% (n=83) in the “maintenance to participants and HCPs” arm and 70.8±27.30% (n=85) in the control arm. The adjusted least squares mean±sewas 80.9±3.19% and 69.0±3.19%, respectively (study arm difference: 12.0%, 95% CI 5.2–18.8%; pversusthe control arm. The mean percentage of rescue medication free days (months 4–6) was significantly greater in participants receiving data on their rescue use compared with controls. ACT scores improved in all study arms with no significant differences between groups.A CIS can improve adherence to maintenance medication and reduce rescue medication use in patients with uncontrolled asthma.
- 1 February 2020
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 145 (2) , AB23
Practical use of Ellipta, a once-daily, dry powder inhaler for children with asthma
- 1 February 2020
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 145 (2) , AB23
Practical use of Ellipta, a once-daily, dry powder inhaler for children with asthma
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , OA3561
Late Breaking Abstract - A connected inhaler system improves adherence to fluticasone furoate/vilanterol in asthma
Background: Poor adherence is a key factor in poor asthma control. A connected inhaler system (CIS) comprising sensors on inhalers, a patient-facing app, and a Healthcare Professional (HCP) dashboard could improve asthma management by improving adherence. Methods: Study 207040 (NCT033800429) is one of the first to investigate the different elements of a CIS in improving adherence. The study had a 24-week, open-label, randomised, multi-centre, parallel group design with 5 treatment arms, in uncontrolled asthmatic patients [Asthma Control Test (ACT) <20] on fixed dose ICS/LABA maintenance therapy. All participants (n=437) received fluticasone furoate/vilanterol Ellipta DPI maintenance therapy, and salbutamol MDI rescue therapy with Propeller Health® sensors attached. Participants were randomised to one of 5 treatment arms: data on (1) maintenance use to participant and HCP; (2) maintenance use to participant; (3) maintenance and rescue use to participant and HCP; (4) maintenance and rescue use to participant; or (5) no data to participant or HCP (control arm). Results: The primary endpoint was the effect of 6 months’ use of a CIS on adherence to maintenance therapy assessed over months 4-6, with the absolute adjusted mean adherence difference in arm 1 (data on maintenance to participant and HCP; 82.0%) being 13.2% (95% CI [6.3%, 20.0%]; p<0.001) greater than arm 5 (control; 68.8%). For arms 2, 3 and 4 the adjusted mean differences were 9.0%, 9.8% and 8.9% respectively versus arm 5 (all statistically significant at the 5% level). Conclusion: The study demonstrates that a CIS can improve adherence to maintenance medication for patients with uncontrolled asthma. Funding: GlaxoSmithKline plc. (207040)
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , OA3561
Late Breaking Abstract - A connected inhaler system improves adherence to fluticasone furoate/vilanterol in asthma
Background: Poor adherence is a key factor in poor asthma control. A connected inhaler system (CIS) comprising sensors on inhalers, a patient-facing app, and a Healthcare Professional (HCP) dashboard could improve asthma management by improving adherence. Methods: Study 207040 (NCT033800429) is one of the first to investigate the different elements of a CIS in improving adherence. The study had a 24-week, open-label, randomised, multi-centre, parallel group design with 5 treatment arms, in uncontrolled asthmatic patients [Asthma Control Test (ACT) <20] on fixed dose ICS/LABA maintenance therapy. All participants (n=437) received fluticasone furoate/vilanterol Ellipta DPI maintenance therapy, and salbutamol MDI rescue therapy with Propeller Health® sensors attached. Participants were randomised to one of 5 treatment arms: data on (1) maintenance use to participant and HCP; (2) maintenance use to participant; (3) maintenance and rescue use to participant and HCP; (4) maintenance and rescue use to participant; or (5) no data to participant or HCP (control arm). Results: The primary endpoint was the effect of 6 months’ use of a CIS on adherence to maintenance therapy assessed over months 4-6, with the absolute adjusted mean adherence difference in arm 1 (data on maintenance to participant and HCP; 82.0%) being 13.2% (95% CI [6.3%, 20.0%]; p<0.001) greater than arm 5 (control; 68.8%). For arms 2, 3 and 4 the adjusted mean differences were 9.0%, 9.8% and 8.9% respectively versus arm 5 (all statistically significant at the 5% level). Conclusion: The study demonstrates that a CIS can improve adherence to maintenance medication for patients with uncontrolled asthma. Funding: GlaxoSmithKline plc. (207040)